VivoSeq
Oncology

B-Cell Malignancy

7

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

B-cell Malignancy is an early-stage landscape with 7 programs across 3 companies. The most active players are BeOne Medicines, Roche, Johnson & Johnson.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

BeOne Medicines

3 programs

PreclinicalRoche logo

Roche

3 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

6programs
Small molecule350%
Monoclonal antibody350%

Modality classified for 86% of 7 pipeline programs.

Analysis

Trial Status

6

clinical trials

Completed2 · 33%
Unknown status2 · 33%
Recruiting2 · 33%

Clinical Trials

Trial Activity

6 trials

An Open-Label, Multicenter Phase I Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-1635 in Patients With B-Cell Malignancies.
Recruiting·CChengdu Suncadia Medicine Co., Ltd.·Phase 1·NCT07583212·180 enrolled
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
Recruiting·BBeOne Medicines·Preclinical·NCT06634589·80 enrolled
Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT02381080·26 enrolled
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
Completed·—·Phase 1/2·NCT03097770·100 enrolled
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19
Unknown status·—·N/A·NCT01864889·12 enrolled
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
Unknown status·—·Phase 1/2·NCT03185494·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)